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Abstract 
Right heart dysfunction is one of the most serious complications following implantation of a left 
ventricular assist device (LVAD), often leading to the requirement for short or long term right 
ventricular support (RVAD). The inflow cannulation site induces major haemodynamic changes and 
so there is a need to optimize the site used depending on the patient's condition. Therefore, this study 
evaluated and compared the haemodynamic influence of right atrial (RAC) and right ventricular 
(RVC) inflow cannulation sites. An in-vitro, variable heart failure, mock circulation loop was used to 
compare RAC and RVC in mild and severe biventricular heart failure (BHF) conditions. In the severe 
BHF condition, higher ventricular ejection fraction (RAC: 13.6%, RVC: 32.7%) and thus improved 
heart chamber and RVAD washout was observed with RVC, which suggested this strategy might be 
preferable for long term support (ie. bridge to transplant or destination therapy) to reduce the risk of 
thrombus formation. In the mild BHF condition, higher pulmonary valve flow (RAC: 3.33 L/min, 
RVC: 1.97 L/min) and lower right ventricular stroke work (RAC: 0.10 W, RVC: 0.13 W) and 
volumes were recorded with RAC. These results indicate an improved potential for myocardial 
recovery, thus RAC should be chosen in this condition. This in-vitro study suggests that RVAD 
inflow cannulation site should be chosen on a patient-specific basis with a view to the support strategy 
to promote myocardial recovery or reduce the risk of long-term complications. 
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Introduction 
The ongoing international shortage of donor hearts necessitates the use of ventricular assist devices 
(VADs) to support end stage heart failure patients to recovery, future transplant or as a destination 
therapy [1]. The majority of clinically apparent ventricular dysfunction is seen in the left ventricle, 
thus the requirement for left ventricular support with a left VAD (LVAD) is the more common 
therapy. However, right ventricular dysfunction is being increasingly recognized as one of the most 
common and serious complications both before and after LVAD insertion [2]. Should right heart 
dysfunction fail to resolve with short term pharmaceutical treatment strategies such as pulmonary 
vasodilators or inotropic agents, reoperation and insertion of a short or long term right VAD (RVAD) 
may be required. The requirement for RVAD placement varies greatly between institutes, and has 
been reported between 5 and 48% of LVAD supported patients [3-5]. 
 
VADs are connected to the heart and great vessels via inflow and outflow cannulae respectively. 
Outflow cannulation is generally achieved through the ascending aorta (LVAD) and the anterior 
aspect of the pulmonary artery (RVAD). The VAD inflow cannulation site represents the primary 
interface between patient and device, and position of the cannula in either the atrium or ventricle 
induces major haemodynamic changes. The choice of inflow cannulation site is often dependant on 
the cannula design or preference of the surgeon and can be limited by anatomical constraints or the 
presence of thrombus within the heart chambers [6, 7]. 
 
The choice of inflow cannulation site should also be based on the treatment strategy and addressed on 
a patient-by-patient basis. For instance, if myocardial recovery is anticipated, efforts should be made 
to unload the heart by reducing ventricular stroke work and end systolic pressure and volume [8, 9]. 
This is becoming increasingly familiar when using VAD therapy to treat cardiogenic shock, which has 
shown relatively high rates of patient recovery and subsequent device removal [10, 11].  In cases 
where long-term support is predicted, such as those implanted for destination therapy, treatment 
should focus on reducing the risk of postoperative complications such as the formation of thrombus. 
Regions of static flow within the heart may predispose the patient to thromboembolic events and can 
be related to the ventricular ejection fraction (EF) and end-diastolic ventricular volume [12-16]. This 
is witnessed in the increasing risk of stroke with a reduction in EF [17, 18]. Therefore, the 
haemodynamic effect of each inflow cannulation site should be considered prior to implantation of 
VAD support. 
 
The haemodynamic effect of LVAD inflow cannulation site has been researched extensively through 
numerical simulations [19], in-vitro evaluation [8] and in-vivo animal models [20-22]. Most agree that 
left ventricular cannulation is the preferred interface site for implantable LVADs [15, 23]. This is due 
to improved LVAD inflow conditions resulting from remnant heart activity, which in turn increases 
pump flow rate and support efficiency [15]. Meanwhile, the improved chamber washout due to 
ventricular contraction combined with the smaller, unloaded left ventricle reduces the risk of 
thromboembolism [24]. However left atrial cannulation allows for easier surgical insertion and also 
promotes the potential for cardiac ventricular recovery by alleviating ventricular workload and 
preserving remaining cardio-myocytes [23, 25].   
 
While inflow to the RVAD is usually delivered via right atrial cannulation (RAC), some institutions 
are now considering right ventricular cannulation (RVC) [26-29]. However, the haemodynamic 
influence of the RVAD inflow site has not been evaluated to the same degree as the LVAD inflow 
cannulation site.  Schlensak et al. (2011) [30], did however investigate the effect of RVAD inflow 
cannulation site in 31 patients supported with dual Thoratec PVAD devices to provide biventricular 
support. The 15 patients with RVC demonstrated higher RVAD flow rates compared to those with 
RAC due to higher RVAD inflow pressures promoting rapid RVAD filling. The increased flow rate 
resulted in improved perfusion of the end organs and subsequently improved kidney and liver 
function. However, RAC was the chosen technique prior to implementation of RVC. Hence, even 
though survival was relatively similar between the two groups, the improved clinical experience with 
VAD support may have promoted the improved results noted in the RVC group. Even though this 
study was published recently, it was completed with the pulsatile first generation devices which are 
rapidly being replaced by the more durable rotary blood pumps (RBPs), particularly with the 
implementation of dual LVADs for biventricular support [28, 31]. A similar study which characterizes 
the effect of RVAD inflow cannulation site for RBPs would serve to enhance future biventricular 
support with continuous flow devices. 
 
Therefore, this study employed an in-vitro mock circulation loop (MCL) to characterize the 
haemodynamic difference between RAC and RVC with continuous flow, biventricular support in mild 
and severe heart failure simulations. The results of this study provide insights into the  hemodynamic 
effect of atrial or ventricular RVAD inflow cannulation site, which may guide inflow site selection so 
as to promote recovery of the right heart and reduce the risk of long-term, postoperative 
complications. 
 
  
Methods 
 Mock Circulation Loop 
A physical five element Windkessel MCL including systemic and pulmonary circulations was used 
for this study [32, 33]. Atrial and ventricular chambers were represented by 40 and 50 mm clear, 
vertical polyvinyl chloride pipes with tee sections connecting the inflow, outflow and heart chamber. 
In brief, ventricular systole was controlled through a series of electropneumatic regulators (ITV2030-
012BS5, SMC Pneumatics, Brisbane, AUS) and 3/2 way solenoid valves (VT325-035DLS, SMC 
Pneumatics, Brisbane, AUS) to provide passively filled heart chambers and variable contractility, 
heart rate and systolic time. Heart rate and systolic time were maintained at 60 beats per minute and 
40% respectively throughout this study. A Starling response was implemented in both left and right 
ventricles which actively controlled ventricular contractility (through electropneumatic regulator 
supply current) based on ventricular preload [34]. Mechanical check valves were used to simulate the 
mitral, aortic, tricuspid and pulmonary valves to ensure unidirectional flow throughout the circuit. 
Four independent Windkessel chambers were employed to simulate lumped systemic and pulmonary 
arterial and venous compliance.  Proportional control valves (EPV-375B, HASS Manufacturing, NY, 
U.S.A.) and socket valves (VMP025.03X.71, Convair Engineering, Epping, Australia) allowed easy 
manipulation of systemic  and pulmonary vascular resistance respectively.   
 
 RVAD Inflow Cannulation 
A BP80 (Bio-Medicus, Inc., Eden Prairie, MN, USA) RBP was initially attached to the MCL through 
the right atrium for RVAD inflow and the pulmonary artery for RVAD outflow. A VentrAssist 
(Ventracor Ltd., Sydney, Australia) rotary LVAD was connected to the MCL via the left ventricle and 
aorta for inflow and outflow cannulation respectively for all tests. A detailed schematic of the MCL 
and VAD connections is shown in Figure 1. The working fluid throughout this study was a 
water/glycerol mixture (60/40% by mass) which, at a room temperature of 22°C, demonstrated similar 
viscosity (3.5 mPa.s) and density (1100 kg.m-3) to that of blood at 37°C.  
 
MCL parameters were manipulated to simulate a mild degree of biventricular heart failure (BHF), 
defined in Table I. LVAD and RVAD support was then initiated where LVAD speed was set at a 
constant 2300 RPM in the mild BHF condition. To characterise the haemodynamic effect of RVAD 
inflow cannulation site at various pump speeds, an RVAD speed ramp test was completed. For this 
test, RVAD speed was increased from 400 to 1500 RPM in increments of 100 RPM or until a suction 
event occurred. A suction event was defined as the right ventricular volume / right atrial pressure 
(RAP) being equal to or less than 0 mL / mmHg. The RVAD inflow cannulation site was then 
changed to the right ventricle before the speed ramp test was repeated. LVAD and RVAD cannulae 
were then clamped and MCL parameters manipulated to represent a severe BHF condition (Table I) 
before the speed ramp tests were repeated. In this severe BHF condition, LVAD speed was set at 2400 
RPM.  
 
To add an additional clinical relevance to the study, LVAD and RVAD speeds were manipulated to 
restore MCL haemodynamics to a pre-defined restored condition (mean aortic pressure: 100 mmHg, 
mean pulmonary arterial pressure (MPAP): 18 mmHg, mean systemic flow rate: 5.0 L/min). This was 
completed in mild and severe BHF conditions to compare the restoring effect of RAC and RVC. 
 
 LAP 
(mmHg) 
MAP 
(mmHg) 
MSQ 
(L/min) 
LVEDV 
(mL) 
RAP 
(mmHg) 
MPAP 
(mmHg) 
MPQ 
(L/min) 
RVEDV 
(mL) 
Mild BHF 10 79 4.0 210 10 19 4.0 190
Severe BHF 12 55 2.3 288 12 16 2.3 253 
Table I - Mock circulation loop haemodynamic parameters used to simulate conditions of mild and severe 
biventricular heart failure (BHF). LAP - left atrial pressure, MAP - mean aortic pressure, MSQ - mean systemic flow 
rate, LVEDV - left ventricular end diastolic volume, RAP - right atrial pressure, MPAP - mean pulmonary arterial 
pressure, MPQ - mean pulmonary flow rate, RVEDV - right ventricular end diastolic volume. 
 
 
Figure 1 - Schematic of the MCL setup for evaluation of RVAD inflow cannulation site. LA - left atrium, MV - mitral 
valve, LV - left ventricle, AoV - aortic valve, AoC - aortic compliance chamber, SQ - systemic flow meter, SVR - 
systemic vascular resistance valve, SVC - systemic venous compliance chamber, RA - right atrium, TV - tricuspid 
valve, RV - right ventricle, PV - pulmonary valve, PAC - pulmonary arterial compliance chamber, PQ - pulmonary 
flow meter, PVR - pulmonary vascular resistance valve, PVC - pulmonary venous compliance chamber, RVAD - 
right ventricular assist device, LVAD - left ventricular assist device, x denotes a valve. 
 
 Data Acquisition 
Haemodynamic and VAD parameters were captured at 100 Hz using a dSPACE acquisition system 
(DS1103, dSPACE, MI, USA). Systemic and pulmonary flow rates were recorded using magnetic 
flow meters (IFC010, KROHNE, Sweden) while LVAD and RVAD outlet flow rates were recorded 
with clamp on ultrasonic flow meters (TS410-10PXL, Transonic Systems, NY, USA). Circulatory and 
VAD pressures were recorded using silicon-based transducers (PX181B-015C5V, Omega 
Engineering, Connecticut, USA) while left and right ventricular volumes were recorded using a 
magnetostrictive level sensor (IK1A, GEFRAN, Italy). 
  
Results 
Results were compared for RAC and RVC in mild and severe BHF conditions at various VAD 
rotational speeds and restored conditions to determine the haemodynamic influence of cannulation 
site. All results presented in this section refer to the right side of the heart and pulmonary circulation 
unless stated otherwise. Results from the speed ramp test for mild and severe BHF in RAC and RVC 
are presented in Figure 2. In the mild BHF condition (Figure 2a) RVAD flow rate (RVADQ) was 
higher in RVC compared with RAC for all RVAD speeds other than when the two had converged at a 
RVAD speed of 1500 RPM (5.1 L/min). This was not translated into total mean pulmonary flow rate 
(MPQ), as RAC consistently had equal-to or higher MPQ than RVC. This can be attributed to the 
ventricular Starling response increasing ventricular contractility due to the higher ventricular end 
diastolic volume (EDV) with RAC. This resulted in increased pulmonary valve flow in RAC 
compared to RVC and indicated that although higher RVADQ is experienced with RVC, the 
ventricular Starling response was able to compensate and result in increased cardiac output with RAC. 
Ventricular ejection fraction (EF) was consistently higher in RVC compared to RAC at RVAD speeds 
above 600 RPM due to the decreased EDV combined with a relatively consistent ventricular stroke 
volume. At low RVAD speeds (ie. 400 - 700 RPM), ventricular stroke work (SW) was relatively 
similar between the two cannulation sites. However as RVAD speed was increased in RAC, the 
weakened ventricle was unable to overcome the high pulmonary arterial pressures, thus decreasing 
stroke volume and SW. In RVC, SW decreased to a lesser degree as the ventricle maintained some 
ejection through the pump as RVAD speed increased. 
 
Similar trends from the mild BHF condition were observed in the severe BHF condition in the RVAD 
speed ramp test. However, a maximum RVAD speed of only 1100 RPM, compared to 1500 RPM in 
mild BHF, was reached due to the reduced Starling response in both left and right ventricles being 
unable assist in balancing flow rates, and hence volumes, between the systemic and pulmonary 
circulations. RVADQ was consistently higher with RVC compared to RAC at lower RVAD speeds. 
However, the diminished ventricular contractility at higher RVAD speeds (due to reduced ventricular 
volume and hence contractility through the ventricular Starling response) resulted in similar RVAD 
preload between the two cannulation sites and therefore comparable RVADQ. MPQ was similar 
between the two cannulation sites, indicating that flow through the pulmonary valve was again higher 
with RAC. MPAP was also comparable between the cannulation sites which, combined with similar 
MPQ, indicated that neither RAC nor RVC is more hydraulically efficient in severe BHF. EF was 
consistently higher in RVC compared to RAC as ventricular ejection occurred through the ventricular 
inflow cannula. SW was generally lower with RAC except at the lowest (400 RPM) and highest (1100 
RPM) RVAD speeds evaluated, thus demonstrating a decreased work load on the ventricle in RAC. 
 
(a) 
 
(b) 
 
Figure 2 - Haemodynamics for right atrial (RAC) and right ventricular (RVC) inflow cannulation in the (a) mild and 
(b) severe biventricular heart failure condition during the speed ramp test. RVADQ – RVAD flow rate, MPQ – mean 
pulmonary flow rate, MPAP – mean pulmonary arterial pressure, RVEF – right ventricular ejection fraction, RVSW 
– right ventricular stroke work (Watts), RPM – revolutions per minute. 
 
To provide a higher degree of clinical relevance to the study, results were taken from the restored 
haemodynamics test for mild and severe BHF in RAC and RVC. The haemodynamics for each 
cannulation site in mild and severe BHF are presented in Table II while ventricular PV loops are 
shown in Figure 3. In mild BHF, a RVAD speed of 900 RPM was required for RAC and RVC to 
maintain restored haemodynamics (MPAP: 18 mmHg, MPQ: 5 L/min), indicating similar efficiency 
between the cannulation sites. However, in severe BHF, a higher RVAD speed was required in RVC 
(1300 RPM) compared to RAC (1100 RPM), indicating that RAC was actually more efficient than 
RVC in severe BHF. This could be due to the high EDV in RAC increasing ventricular contractility 
through the ventricular Starling response, even with its diminished sensitivity in severe BHF. As 
expected, right atrial pressure (RAP) was lower in RAC compared to RVC as the RVAD pumped 
fluid from the cannulated chamber. RVAD flow rate was higher in RVC (mild BHF: 3.03 L/min, 
severe BHF: 4.8 L/min) compared to RAC (mild BHF: 2.67 L/min, severe BHF: 3.9 L/min) due to the 
increase preload from ventricular systole in RVC. Evaluation of the ventricular PV loops revealed 
increased EF in RVC (mild BHF: 31.8%, severe BHF: 32.7%) compared to RAC (mild BHF: 27.6%, 
severe BHF: 13.6%) in both conditions, indicating increased ventricular washout with RVC. While 
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values were both low in comparison with a healthy right ventricle, SW was increased with RVC 
compared to RAC in mild and severe BHF.  
 
Condition Mild BHF Severe BHF 
Cannulation Site RAC RVC RAC RVC 
RVADS (RPM) 900 900 1100 1300 
RAP (mmHg) 6.5 9.0 4.8 6.5 
MPAP (mmHg) 18 18 18 18 
RVPsys (mmHg) 28 27 23 20 
MPQ (L/min) 5.0 5.0 5.0 5.0 
RVADQ (L/min) 2.67 3.03 3.9 4.8 
RVVsys (mL) 110 120 108 78 
RVVdias (mL) 152 176 125 116 
EF (%) 27.6 31.8 13.6 32.7 
SW (Watts) 0.10 0.13 0.03 0.05 
Table II – Haemodynamics for the restored test with right atrial (RAC) and right ventricular (RVC) inflow 
cannulation in mild and severe biventricular heart failure (BHF) conditions. RVADS – RVAD speed, RAP – right 
atrial pressure, MPAP – mean pulmonary arterial pressure, RVPsys – right ventricular systolic pressure, MPQ – 
mean pulmonary flow rate, RVADQ – RVAD flow rate, RVVsys – systolic right ventricular volume, RVVdias – 
diastolic right ventricular volume, EF – right ventricular ejection fraction, SW – right ventricular stroke work 
(Watts), RPM – revolutions per minute. 
 
(a) 
 
(b) 
 
Figure 3 – Pressure-volume loops for right atrial (RAC) and right ventricular (RVC) inflow cannulation shown for 
conditions of mild (a) and severe (b) right heart failure. RVP – right ventricular pressure, RVV – right ventricular 
volume. 
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Discussion 
First generation RVADs are being phased out in favor of the more durable RBPs, particularly as the 
adaptation of a rotary LVAD for right ventricular support gains clinical acceptance [28, 35]. The 
primary interface between RBPs and the patient is the inflow cannula, with inflow cannula placement 
in either the atrium or ventricle potentially inducing major haemodynamic changes. Whilst rotary 
LVAD inflow cannula placement has been evaluated extensively [8, 19-22], the haemodynamic 
influence of rotary RVAD inflow cannula placement has not been previously characterized. There is, 
therefore, a need to find the most appropriate inflow cannulation site to improve the performance of 
the cardiac-RVAD interaction to suit the support strategy selected for each patient.  
 
Although the results of LVAD inflow cannulation site cannot be directly translated to RVAD inflow 
cannulation site due to different ventricular function (eg. sensitivity of the Starling response) and 
vascular parameters, our study showed that some similar trends exist. For instance, previous in-vitro 
[8] and in-vivo [20] studies have shown that left atrial cannulation reduced left ventricular stroke 
work compared to left ventricular cannulation which may encourage myocardial recovery [36]. In our 
study, RAC reduced SW in almost all cases with exceptions at the lowest RVAD speeds, when 
RVAD support was not significant enough to alter right ventricular function, and at the highest 
RVAD speeds, when over-pumping resulted in diminished right ventricular contractility due to the 
Starling response. Reduced right ventricular volumes were also noted with RAC in the mild BHF 
condition, thus reducing the stress on the ventricular wall. Ventricular unloading by reducing SW and 
EDV is vital for patients identified for bridge to recovery treatment, as the aim of this strategy is to 
reduce the workload of the heart until it recovers [37].  
 
Another advantage when aiming for bridge-to-recovery therapy is maintaining flow through the 
pulmonary valve. In our mild BHF condition, right ventricular systolic pressure was higher in RAC as 
ventricular ejection could not occur through the RVAD inflow cannula. This resulted in increased 
pulmonary valve flow with RAC which may prevent the valve from becoming stenotic and reduce the 
risk of thrombus formation around the valve [20]. Meanwhile, RAC allows for easier surgical 
insertion off bypass, particularly for the extracorporeal placed devices, and promotes potential for 
myocardial recovery through preservation of the remaining cardio-myocytes by eliminating the need 
to core the apex. Therefore, RAC presents several advantages over RVC in a mild BHF condition 
with a view to myocardial recovery and should be selected to treat this patient population. 
 
With a view to long term LVAD support, the efficiency of the pump becomes important to reduce 
power consumption, thus increasing battery life and reducing mechanical wear. McGee (2008) [37] 
suggested that RVC provides better draining and higher flows compared to RAC, and similar 
conclusions have been made for LVAD inflow cannulation site [8, 20, 21]. Schlensak (2011) [30] 
reported higher RVAD flow with RVC, however this study was completed with first generation 
devices which have different operating characteristics to RBPs. In our study, RVADQ was higher 
with RVC in almost all conditions. This was particularly noticeable at low RVAD speeds when the 
right ventricle was severely dilated and the right ventricular Starling response increased RVAD 
preload with RVC. However, the higher RVADQ did not translate to a higher MPQ as the larger EDV 
in RAC increased right ventricular contractility through the Starling response, thus preserving ejection 
through the pulmonary valve. This was less noticeable in the severe BHF condition due to the 
diminished Starling sensitivity; however these results indicate that neither RAC or RVC significantly 
increases RBP support efficiency. 
 
Neurologic complications remain one of the most serious adverse events while receiving mechanical 
circulatory support [38], thus there is a need to promote heart chamber and RBP washout to reduce 
the risk of thrombus formation, stroke and pulmonary embolism [16, 39, 40]. As is the case with 
LVAD support, the higher and more pulsatile RVADQ with RVC may improve the washout of the 
rotary RVAD and reduce the risk of thrombus forming in the pump [23]. Improved washout (ie. 
higher EF) was also noted in the right ventricle in our study with RVC, thus potentially reducing the 
risk of thrombus formation in the heart chamber. The increased EF in RVC can be attributed to the 
remnant ventricular contractility forcing ejection through the RBP. This is, however, not possible in 
RAC and right ventricular ejection is confined solely through the pulmonary valve. Therefore, the 
lower EF recorded with RAC, particularly in the severe BHF case, may predispose the right ventricle 
to thrombus formation [18, 41]. It is for this reason that RVC should be chosen for long-term RVAD 
support with a view to transplant or destination therapy. This choice, however, is often dependant on 
the preference of the surgeon, and can be limited by anatomical constraints or the pre-operative 
presence of thrombus within a vessel [6, 7]. 
 
  
Conclusion 
In-vitro investigation of right VAD inflow cannula site in a MCL revealed that cannulation of the 
right ventricle may benefit patients suffering from severe BHF with a view to long term RVAD 
support such as bridge to transplant or destination therapy. This is due to the remnant right ventricular 
contractility improving RBP and heart chamber washout, thus reducing the potential for thrombus 
formation. RAC should be preferred in a mild BHF condition with a view to myocardial recovery to 
increase flow through the pulmonary valve, reduce right ventricular work and preserve the 
myocardium. However, the conclusions drawn from this study can only be taken as a guide and, 
ultimately, inflow cannula placement will be chosen based on patient constraints, device availability 
and the preference of the surgeon. Future work would benefit from a review of performance in-vivo 
for confirmation of the recommendations made from this in-vitro study. 
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Figure 1 - Schematic of the MCL setup for evaluation of RVAD inflow cannulation site. LA - left atrium, MV - mitral 
valve, LV - left ventricle, AoV - aortic valve, AoC - aortic compliance chamber, SQ - systemic flow meter, SVR - 
systemic vascular resistance valve, SVC - systemic venous compliance chamber, RA - right atrium, TV - tricuspid 
valve, RV - right ventricle, PV - pulmonary valve, PAC - pulmonary arterial compliance chamber, PQ - pulmonary 
flow meter, PVR - pulmonary vascular resistance valve, PVC - pulmonary venous compliance chamber, RVAD - 
right ventricular assist device, LVAD - left ventricular assist device, x denotes a valve. 
  
(a) 
 
(b) 
 
Figure 2 - Haemodynamics for right atrial (RAC) and right ventricular (RVC) inflow cannulation in the (a) mild and 
(b) severe biventricular heart failure condition during the speed ramp test. RVADQ – RVAD flow rate, MPQ – mean 
pulmonary flow rate, MPAP – mean pulmonary arterial pressure, RVEF – right ventricular ejection fraction, RVSW 
– right ventricular stroke work (Watts), RPM – revolutions per minute. 
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Figure 3 – Pressure-volume loops for right atrial (RAC) and right ventricular (RVC) inflow cannulation shown for 
conditions of mild (a) and severe (b) right heart failure. RVP – right ventricular pressure, RVV – right ventricular 
volume. 
 
  
0 50 100 150 200
0
5
10
15
20
25
30
RVV (mL)
R
V
P
 (m
m
H
g)
 
0 50 100 150 200
0
5
10
15
20
25
30
RVV (mL)
R
V
P
 (m
m
H
g)
 
 
RAC 
RVC 
RAC 
RVC
List of Tables 
 
 LAP 
(mmHg) 
MAP 
(mmHg) 
MSQ 
(L/min) 
LVEDV 
(mL) 
RAP 
(mmHg) 
MPAP 
(mmHg) 
MPQ 
(L/min) 
RVEDV 
(mL) 
Mild BHF 10 79 4.0 210 10 19 4.0 190 
Severe BHF 12 55 2.3 288 12 16 2.3 253 
Table I - Mock circulation loop haemodynamic parameters used to simulate conditions of mild and severe 
biventricular heart failure (BHF). LAP - left atrial pressure, MAP - mean aortic pressure, MSQ - mean systemic flow 
rate, LVEDV - left ventricular end diastolic volume, RAP - right atrial pressure, MPAP - mean pulmonary arterial 
pressure, MPQ - mean pulmonary flow rate, RVEDV - right ventricular end diastolic volume. 
  
Condition Mild BHF Severe BHF 
Cannulation Site RAC RVC RAC RVC 
RVADS (RPM) 900 900 1100 1300 
RAP (mmHg) 6.5 9.0 4.8 6.5 
MPAP (mmHg) 18 18 18 18 
RVPsys (mmHg) 28 27 23 20 
MPQ (L/min) 5.0 5.0 5.0 5.0 
RVADQ (L/min) 2.67 3.03 3.9 4.8 
RVVsys (mL) 110 120 108 78 
RVVdias (mL) 152 176 125 116 
EF (%) 27.6 31.8 13.6 32.7 
SW (Watts) 0.10 0.13 0.03 0.05 
Table II – Haemodynamics for the restored test with right atrial (RAC) and right ventricular (RVC) inflow 
cannulation in mild and severe biventricular heart failure (BHF) conditions. RVADS – RVAD speed, RAP – right 
atrial pressure, MPAP – mean pulmonary arterial pressure, RVPsys – right ventricular systolic pressure, MPQ – 
mean pulmonary flow rate, RVADQ – RVAD flow rate, RVVsys – systolic right ventricular volume, RVVdias – 
diastolic right ventricular volume, EF – right ventricular ejection fraction, SW – right ventricular stroke work 
(Watts), RPM – revolutions per minute. 
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